Gritstone bio, Inc.
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for tre… Read more
Gritstone bio, Inc. (GRTSQ) - Net Assets
Latest net assets as of June 2024: $22.19 Million USD
Based on the latest financial reports, Gritstone bio, Inc. (GRTSQ) has net assets worth $22.19 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($142.54 Million) and total liabilities ($120.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $22.19 Million |
| % of Total Assets | 15.57% |
| Annual Growth Rate | -32.27% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 40.51 |
Gritstone bio, Inc. - Net Assets Trend (2020–2023)
This chart illustrates how Gritstone bio, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gritstone bio, Inc. (2020–2023)
The table below shows the annual net assets of Gritstone bio, Inc. from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $51.85 Million | -69.64% |
| 2022-12-31 | $170.78 Million | -20.97% |
| 2021-12-31 | $216.09 Million | +29.60% |
| 2020-12-31 | $166.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gritstone bio, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33325900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $711.41 Million | 1372.06% |
| Total Equity | $51.85 Million | 100.00% |
Gritstone bio, Inc. Competitors by Market Cap
The table below lists competitors of Gritstone bio, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Next.e.GO N.V.
NASDAQ:EGOXF
|
$0.93 |
|
Exobox Tech Corp
PINK:EXBX
|
$0.93 |
|
Neurogenesis Inc
PINK:NEUN
|
$0.93 |
|
MotorVac Technologies Inc
PINK:MVAC
|
$0.93 |
|
Transtech Industries Inc
PINK:TRTI
|
$0.93 |
|
LEEP Inc
PINK:LPPI
|
$0.93 |
|
Interact-TV Inc
PINK:ITVI
|
$0.93 |
|
Vasamed Inc
PINK:VSMD
|
$0.93 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gritstone bio, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 170,781,000 to 51,850,000, a change of -118,931,000 (-69.6%).
- Net loss of 138,490,000 reduced equity.
- New share issuances of 8,092,000 increased equity.
- Other factors increased equity by 11,467,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-138.49 Million | -267.1% |
| Share Issuances | $8.09 Million | +15.61% |
| Other Changes | $11.47 Million | +22.12% |
| Total Change | $- | -69.64% |
Book Value vs Market Value Analysis
This analysis compares Gritstone bio, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $3.51 | $0.00 | x |
| 2021-12-31 | $3.13 | $0.00 | x |
| 2022-12-31 | $1.97 | $0.00 | x |
| 2023-12-31 | $0.53 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gritstone bio, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -267.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10404.96%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 3.43x
- Recent ROE (-267.10%) is below the historical average (-108.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -63.16% | -3042.00% | 0.02x | 1.33x | $-121.99 Million |
| 2021 | -34.75% | -160.72% | 0.17x | 1.29x | $-96.69 Million |
| 2022 | -70.08% | -1291.26% | 0.04x | 1.41x | $-136.77 Million |
| 2023 | -267.10% | -10404.96% | 0.01x | 3.43x | $-143.68 Million |
Industry Comparison
This section compares Gritstone bio, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gritstone bio, Inc. (GRTSQ) | $22.19 Million | -63.16% | 5.42x | $0.93 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |